Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifemd, Inc. on June 16, 2023, covering events occurring on June 15, 2023. The filing addresses a modification to the employment agreement and long-term incentive awards for Eric Yecies, the Company's General Counsel and Chief Compliance Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments rather than financial performance results.
Material Changes
Effective June 15, 2023, the Company entered into a Second Amendment to the Employment Agreement with Eric Yecies. The material changes involve the restructuring of his equity compensation:
- Cancellations: 200,000 stock options and 105,000 performance share units were cancelled.
- New Awards:
- 150,000 restricted shares with time-based vesting (12,500 immediate, 37,500 on Nov 20, 2023, and 100,000 on Jan 1, 2024).
- 150,000 restricted shares subject to net revenue and adjusted EBITDA margin milestones over four years.
- 75,000 restricted shares subject to personal performance milestones over two years.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or general outlook commentary. However, it outlines specific contingencies regarding the new equity awards:
- Forfeiture Risk: Unvested awards are forfeited upon termination for "Cause."
- Acceleration Triggers: 100% of awards vest immediately in the event of termination without "Cause," for "Good Reason," or upon a "Change of Control."
Investor Verification Checklist
- Review the full text of the Second Amendment to the Employment Agreement (Exhibit 10.3) for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Examine the Restricted Stock Award Agreement (Exhibit 10.4) to understand the specific metrics required for the 150,000 performance-based shares.
- Assess the impact of the cancelled options and performance units on the Company's total share count and dilution.
- Verify the vesting schedule dates against the Company's fiscal calendar to estimate future expense recognition.